Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Amylyx Pharmaceuticals, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 10/04/2023 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 3.4% stake in Amylyx Pharmaceuticals, Inc. |
| 08/24/2023 |
4
| FRATES JAMES M (CFO) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Exercised 18,165 options to buy
@ $6.88, valued at
$125k
|
|
| 08/17/2023 |
4
| Morningside Venture Investments Ltd (10% Owner) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Gifted 2,000,000 shares
@ $0 |
|
| 08/17/2023 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 6.9% stake in Amylyx Pharmaceuticals, Inc. |
| 08/17/2023 |
4
| Mazzariello Gina (Chief Legal Officer) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Sold 6,164 shares
@ $20.8771, valued at
$128.7k
|
|
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/12/2023 |
4
| Firestone Karen (Director) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Granted 3,908 options to buy
@ $26.25, valued at
$102.6k
|
|
| 06/12/2023 |
4
| MILNE GEORGE M JR (Director) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Granted 16,985 options to buy
@ $26.25, valued at
$445.9k
|
|
| 06/12/2023 |
4
| Quimi Daphne (Director) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Granted 16,985 options to buy
@ $26.25, valued at
$445.9k
|
|
| 06/12/2023 |
4
| FONTEYNE PAUL R. (Director) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Granted 16,985 options to buy
@ $26.25, valued at
$445.9k
|
|
| 06/09/2023 |
SC 13G
| GOLDMAN SACHS GROUP INC reports a 5.4% stake in AMYLYX PHARMACEUTICALS, INC. |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/24/2023 |
4
| Olinger Margaret (Chief Commercial Officer) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Gifted 1,580 shares
@ $0 |
|
| 05/19/2023 |
4
| Mazzariello Gina (Chief Legal Officer) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Gifted 500 shares
@ $0 |
|
| 05/18/2023 |
4
| FRATES JAMES M (CFO) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Sold 32,000 shares
@ $26.9266, valued at
$861.7k
Sold 500 shares
@ $27.6, valued at
$13.8k
Exercised 32,500 options to buy
@ $6.88, valued at
$223.6k
|
|
| 05/17/2023 |
4
| Yeramian Patrick D (Chief Medical Officer) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Sold 11,965 shares
@ $29.0312, valued at
$347.4k
Exercised 2,201 options to buy
@ $0.37, valued at
$814.4
Exercised 9,764 options to buy
@ $6.88, valued at
$67.2k
|
|
| 05/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/26/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 04/26/2023 |
3/A
| Form 3/A - Initial statement of beneficial ownership of securities: [Amend] |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/03/2023 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 12.9% stake in Amylyx Pharmaceuticals, Inc. |
| 03/31/2023 |
4
| Morningside Venture Investments Ltd (10% Owner) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.|
Txns:
| Sold 29,048 shares
@ $30.45, valued at
$884.5k
|
|
|
|
|